Lori Jukofsky

1.8k total citations
16 papers, 256 citations indexed

About

Lori Jukofsky is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lori Jukofsky has authored 16 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lori Jukofsky's work include Cancer-related Molecular Pathways (4 papers), RNA modifications and cancer (3 papers) and Genomics and Chromatin Dynamics (3 papers). Lori Jukofsky is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), RNA modifications and cancer (3 papers) and Genomics and Chromatin Dynamics (3 papers). Lori Jukofsky collaborates with scholars based in United States, Switzerland and United Kingdom. Lori Jukofsky's co-authors include Ian D. Krantz, Karen Russell, Mark Magnusson, Jeffrey E. Ming, Ketan D. Patel, Gwen Nichols, Jianguo Zhi, Steven Blotner, Steven A. Middleton and Ryan Geschwindt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Lori Jukofsky

15 papers receiving 254 citations

Peers

Lori Jukofsky

ONCOL

GENET

PRM

PPCH

Dirk Reutzel Germany

Takefumi Ishidao Japan

Jacqueline Dickson United Kingdom

Dianne Chadwick Canada

Ursula Grazini United Kingdom

Michael Nead United States

Jéssica González Spain

Dominique Stoppa‐Lyonnet France

Jennifer VanOudenhove United States

Baeck-Seung Lee United States

Dirk Reutzel Germany

Lori Jukofsky

256 ×1.7

57 ×0.7

ONCOL

113 ×1.5

GENET

28 ×0.7

PRM

63 ×1.7

PPCH

Citations per year, relative to Lori Jukofsky Lori Jukofsky (= 1×) peers Dirk Reutzel

Countries citing papers authored by Lori Jukofsky

Since Specialization

Citations

This map shows the geographic impact of Lori Jukofsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Jukofsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Jukofsky more than expected).

Fields of papers citing papers by Lori Jukofsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Jukofsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Jukofsky. The network helps show where Lori Jukofsky may publish in the future.

Co-authorship network of co-authors of Lori Jukofsky

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Jukofsky. A scholar is included among the top collaborators of Lori Jukofsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Jukofsky. Lori Jukofsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Shitara, Kohei, Mahmut Gümüş, Filippo Pietrantonio, et al.. (2025). Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.. Journal of Clinical Oncology. 43(17_suppl). 1 indexed citations

Garon, Edward B., Melissa L. Johnson, Aaron Lisberg, et al.. (2021). LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. Annals of Oncology. 32. S1326–S1327. 26 indexed citations

Pradier, Melanie F., Bernhard Reis, Lori Jukofsky, et al.. (2019). Case-control Indian buffet process identifies biomarkers of response to Codrituzumab. BMC Cancer. 19(1). 278–278. 3 indexed citations

Chen, Gong, Ya‐Chi Chen, Bernhard Reis, et al.. (2018). Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 9(12). 10436–10444. 13 indexed citations

Razak, Albiruni Abdul, Lia Gore, Carolyn D. Britten, et al.. (2016). A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. European Journal of Cancer. 69. S21–S22. 5 indexed citations

Martinelli, Giovanni, Karen Yee, Lori Jukofsky, et al.. (2016). Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist. Blood. 128(22). 2843–2843. 7 indexed citations

Puig, Óscar, Ya‐Chi Chen, Eliezer Shochat, et al.. (2014). Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) (NCT01507168).. Journal of Clinical Oncology. 32(15_suppl). e15090–e15090. 1 indexed citations

Siu, Lillian L., Antoîne Italiano, Wilson H. Miller, et al.. (2014). Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2535–2535. 45 indexed citations

Yee, Karen, Giovanni Martinelli, Sarit Assouline, et al.. (2013). Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. Blood. 122(21). 498–498. 18 indexed citations

10.

Nichols, Gwen, Monica Reckner, Lyubomir T. Vassilev, et al.. (2011). Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3039–3039. 6 indexed citations

11.

Andreeff, Michael, Kensuke Kojima, Vivian Ruvolo, et al.. (2011). Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Blood. 118(21). 1545–1545. 3 indexed citations

12.

DeScipio, Cheryl, Lori Schneider, Terri L. Young, et al.. (2005). Subtelomeric deletions of chromosome 6p: Molecular and cytogenetic characterization of three new cases with phenotypic overlap with Ritscher?Schinzel (3C) syndrome. American Journal of Medical Genetics Part A. 134A(1). 3–11. 54 indexed citations

13.

Russell, Karen, Jeffrey E. Ming, Ketan D. Patel, et al.. (2001). Dominant paternal transmission of Cornelia de Lange syndrome: A new case and review of 25 previously reported familial recurrences. American Journal of Medical Genetics. 104(4). 267–276. 41 indexed citations

14.

Krantz, Ian D., Emma L. Tonkin, Marcella Devoto, et al.. (2001). Exclusion of linkage to the CDL1 gene region on chromosome 3q26.3 in some familial cases of Cornelia de Lange syndrome. American Journal of Medical Genetics. 101(2). 120–129. 1 indexed citations

15.

Krantz, Ian D., Emma Tonkin, Melanie Smith, et al.. (2001). Exclusion of linkage to theCDL1 gene region on chromosome 3q26.3 in some familial cases of Cornelia de Lange syndrome. American Journal of Medical Genetics. 101(2). 120–129. 25 indexed citations

16.

Lee, Laura, et al.. (2000). Chromosomal localization, genomic characterization, and mapping to the Noonan syndrome critical region of the human Deltex (DTX1) gene. Human Genetics. 107(6). 577–581. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact